You are here: Industry Insights > PTC299

News List

PTC Therapeutics Initiates Second Stage of FITE19 Trial Evaluating PTC299 for COVID-19 americanpharmaceuticalreview
February 19, 2021
PTC Therapeutics announced the initiation of the second stage of the FITE19 clinical trial to assess PTC299 in COVID-19 patients.
PTC Therapeutics Announces Initiation of Phase 2/3 Clinical Trial in Australia to Evaluate PTC299 for the Treatment of COVID-19 prnasia
November 16, 2020
PTC Therapeutics, Inc., today announced the initiation of a Phase 2/3 trial called FITE19 to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.
PTC Announces the Phase 2/3 Clinical Trial to Evaluate PTC299 for COVID-19 americanpharmaceuticalreview
June 29, 2020
PTC Therapeutics announced the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase 2/3 trial to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.
PTC Begins Phase II/III Trial of PTC299 in COVID-19 contractpharma
June 18, 2020
PTC299 has a novel dual-mechanism of action that has the potential to address high viral replication and uncontrolled inflammatory response.